Paper Details

  1. Home
  2. Paper Details

A Likely Case of Abemaciclib-Induced Hyperpigmentation in a Patient With Metastatic Breast Cancer.

Author: MorleyKeith, PorterHannah, Salusti-SimpsonMichela

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

Abemaciclib, a cyclin-dependent kinase inhibitor used for breast cancer, may cause hyperpigmentation of the skin. This case report highlights the importance of being aware of potential cutaneous side effects of this drug.
Paper Details　
Original Abstract of the Article :
We report a case of a 64-year-old female with a past medical history of invasive right breast adenocarcinoma presented with diffuse hyperpigmentation of her skin after admission to the hospital for an infected breast implant. She had no recollection of a similar cutaneous reaction in her past. The p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484784/

データ提供：米国国立医学図書館（NLM）

Abemaciclib and Hyperpigmentation: A Case Study in the Desert of Cancer Treatment

The battle against cancer is a complex and often arduous journey. This case study examines a patient with metastatic breast cancer who developed hyperpigmentation after being treated with abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor (CDK 4/6). The researchers highlight the rarity of this specific side effect and the limited research on CDK 4/6 inhibitors. This case study underscores the importance of being vigilant for potential side effects, even with relatively new medications. It also emphasizes the need for continued research to better understand the long-term effects of these drugs.

Exploring the Side Effects of Cancer Treatment

The case study provides a valuable glimpse into the potential side effects of abemaciclib, a relatively new drug in the landscape of cancer treatment. The occurrence of hyperpigmentation highlights the need for further research to better understand the long-term effects and risks associated with this medication. This study emphasizes the importance of careful monitoring and communication between healthcare providers and patients, particularly when using novel treatments.

Navigating the Terrain of Cancer Treatment

The desert of cancer treatment is often filled with unexpected challenges. This case study serves as a reminder that even with promising advancements, there are still unknown risks and side effects. It encourages us to be proactive in our understanding of treatment options and to work closely with healthcare professionals to navigate the complex terrain of cancer care.

Dr.Camel's Conclusion

The case study highlights the importance of being vigilant for potential side effects, even with relatively new medications. It also emphasizes the need for continued research to better understand the long-term effects of these drugs.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-09-28
Further Info :

Pubmed ID

36159365

DOI: Digital Object Identifier

PMC9484784

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.